At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,838 enrolled
Drug / intervention
Hepatitis B Vaccinationbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
In Brief
A Phase 3 clinical trial evaluating Hepatitis B Vaccination for Hepatitis B Vaccines. Completed, enrolled 2,838 participants across 26 sites in 6 countries.
Detailed Summary
A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B Vaccines
CountriesBelgium, Canada, Finland, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
First PostedJan 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedJan 24, 2018
Enrollment StartDec 14, 2017
Primary CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.4 years ago
Interventions
Hepatitis B Vaccinationbiological
Hepatitis B Vaccination